Date and Nature of Exchange Communication

Shivalik Rasayan Limited received a communication from the National Stock Exchange of India Ltd (NSE) on July 29, 2026, referencing an observation that "Financial results submitted are not as per format prescribed by SEBI- Consolidated balancing figure note missing."

Company’s Clarification on Trading Volume and Financial Results

The company's response, signed by Company Secretary & Compliance Officer Parul Choudhary (ACS: 34854), stated: "We have reviewed the observation by Exchange; we would like to inform you that the consolidated balancing figure note was inadvertently missed and the revised results are annexed for your review and consideration."

Regulatory Compliance Reference

The document extensively references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically:

  • Regulation 33 for submission of Audited Financial Results
  • Regulation 33(3)(d) regarding the auditor's report with unmodified opinion
  • Regulation 30 for disclosure requirements related to director changes
  • SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

Details of Financial Results and Board Meeting Outcomes

The Board of Directors meeting held on May 27, 2026 (commencing at 3:30 pm and concluding at 4:40 pm) approved the following:

Financial Results for Quarter and Year Ended March 31, 2026:

  • Standalone Net Profit: ₹817.26 lakhs for FY26 (compared to ₹1,386.68 lakhs in FY25)
  • Consolidated Net Profit: ₹1,796.88 lakhs for FY26 (compared to ₹2,042.24 lakhs in FY25)
  • Consolidated Revenue: ₹36,800.32 lakhs for FY26 (compared to ₹31,067.31 lakhs in FY25)
  • Segment Revenue Breakdown (Consolidated FY26):
  • Agrochemicals: ₹15,125.67 lakhs
  • Active Pharma Ingredient (API): ₹904.79 lakhs
  • Pharma Formulation: ₹19,776.97 lakhs
  • Unallocated other operating revenue: ₹992.89 lakhs

Dividend Declaration:

  • Recommended a final dividend @ 10% on Equity Shares of ₹5/- each (50 paise per equity share) for FY 2025-26, subject to shareholder approval

Auditor Appointments:

  • M/s Amar Sharma & Co resigned as Internal Auditor due to other pre-occupations
  • M/s Arun Agarwal & Co appointed as Internal Auditor for FY 2026-27
  • Cheena & Associates appointed as Cost Auditor for FY 2026-27

Management Changes:

  • Mr. Sanjay Bansal resigned as Non-Executive Director due to personal reasons
  • In view of this cessation, the Board reconstituted four committees effective May 27, 2026:
  • Audit Committee
  • Stakeholders Relationship Committee
  • Nomination and Remuneration Committee
  • Risk Management Committee

Auditor Reports:

  • Rahul Chaudhary & Associates, Chartered Accountants (Firm Registration No 033971N) issued audit reports with unmodified opinion on both standalone and consolidated financial results
  • The consolidated results include associate company Medicamen Biotech Limited, which contributed:
  • Total assets: ₹37,198.84 lakhs
  • Quarterly revenue: ₹6,238.18 lakhs (Q4 FY26)
  • Annual revenue: ₹20,088.29 lakhs (FY26)
  • Quarterly net profit: ₹444.70 lakhs (Q4 FY26)
  • Annual net profit: ₹979.64 lakhs (FY26)

Segment Information:

The company operates in three business segments: Agro Chemical, Pharma API & Pharma Formulations

Topic Tags: Regulatory Response, Financial Results Clarification, Dividend Declaration, Management Change, Board Committee Reconstitution, Auditor Appointment, Compliance with SEBI LODR